The advent of new drugs to treat tuberculosis and enhanced funding now permit randomized, controlled trials of shortened-duration, all-oral treatments for rifampin-resistant tuberculosis.

Rifampin-resistant tuberculosis has traditionally been treated with 18-to-24-month regimens, but shorter, all-oral regimens may offer efficacious alternatives. New research findings are summarized ...

"For decades, poor treatment options and low-quality evidence plagued care for patients with rifampin-resistant tuberculosis," they wrote. "These findings support the use of three new, all-oral ...